Home / News / Tagged: wgs

How Dante Labs Can Help You Get Your Diagnosis

How Dante Labs Can Help You Get Your Diagnosis

It takes on average 7.6 years for a Rare Disease patient to receive a diagnosis.  If you’ve seen our Facts posted daily on Twitter and Facebook, then you’ll know this period of time is called the, ‘Rare Disease Odyssey’. During this length of time patients go undiagnosed or misdiagnosed, and are termed, ‘medical refugees’. Instead of receiving a standard course of medicine, Rare Disease patients endure; repetitive rounds of testing, miss-interpretations of results, and tracking down specialists. However, this 7-year long Odessey has the potential to be shortened to months using a technology called ‘Whole Genome Sequencing’ (WGS).

80% of Rare Diseases are of a ‘genetic origin’. This means that within our 3 billion long, ATCG-coded genome, lies many of the answers as to why certain rare diseases or ‘unexplainable symptoms’ occur. If patients  are able to access their genomes, they could be able to understand what rare disease they harbour and begin to understand its’ genetic basis.

This is where WGS comes in.

WGS is a tool used by scientists to identify the order of  our ATCG-lettered genomes. Each person has a slightly different sequence of letters, which is what causes variation and, in some cases, Rare Diseases. Certain arrangements of these letters within our genome are associated with Rare Diseases. For example, variations of the lettered arrangement in  the ‘COL5A1’ gene, are thought to contribute to Ehlers Danlos. So where can you get WGS, to understand the sequence of your genetic code?

Phase 1 of  Dante Labs’ action plan to help tackle difficulties faced by undiagnosed/misdiagnosed patients is:

  1. To offer discounted WGS tests for Rare Disease patients ($299). To help those in need now of a diagnosis. However, we aren’t stopping at providing you with the data.

Phase 2 of our action plan for you is:

  1. To provide you with the services that can help to interpret the data and guide you through the diagnosis process  with our optional ‘Customized Report’ and our additional ‘Secondary Report’. Both Reports form part of our developed ‘’Two-Tiered’ approach.

This First Tier (the Customized Report) is an option that we provide (free of charge) to patients who have a specific interest for a specific condition or disease, for example Epilepsy, Periodic Paralysis).If you choose “Periodic Paralysis”, then we will generate a Periodic Paralysis Panel, containing all the variants. The variants found and interpreted  are recurrent and have been well-documented and associated with the symptoms  reported.

The Second Tier (our Secondary Report) includes variants with similar symptoms to your chosen disease of interest.  What we call an ‘expanded gene panel’. We have found from our experience of helping Rare Disease patients that with complex diseases, up to 20% of patients are misdiagnosed with the wrong disease. Therefore, this specially curated Secondary Report has proven to be a very useful tool for both patients and doctors to achieve a precise diagnosis, and prevent the ‘diagnostic odyssey’ experienced by Rare Disease patients.

The Third and Final Phase of our plan is:

  1. The opportunity you get to help a Rare Disease patient in the future. This is because proceeds raised during Rare Disease  Month will be used to fund free genetic testing to Rare Disease patients in need.

So if this list of benefits isn’t enough to get your whole genome sequenced at Dante Labs during Rare Disease Month, take a look at another of our articles[https://www.dantelabs.com/blogs/news/seven-years-of-searching-can-turn-into-months-using-your-own-genetics].

But why not consider ‘bare-ing your rare’ today, to help yourself and help someone else.

 #bareyourare #showyourstripes

Seven years of searching can turn into months using your own genetics

Are you able to cast your mind back to seven and a half years ago?  For much of our 7 billion-strong population the memory that arises will be of little significance, but for the millions of rare disease patients out there, this memory is has led and changed the course of their lives.

It takes on average 7.6 years for a rare disease patient to receive a diagnosis. This period of time is known as the rare disease odyssey, where patients are termed ‘medical refugees’. This is because, instead of receiving a standard course of medicine, rare disease patients are tasked with enduring; repetitive rounds of testing, miss-interpretations of results, and tracking down specialists. Yet still these patients manage to persevere with a distinct determination coming from what can be a frustrating and intolerable heartache. 

It is estimated that there are 350 million people living with rare diseases across the globe. If these 350 million people were to live in a single country, it would be the third most populous country in the world. These shocking but verifiable facts clearly demonstrate the widespread need to understand and tackle rare diseases. However, our lack of scientific understanding of these diseases has led the snow-balling of detrimental effects, left to be felt by rare disease patients.

Hope is around the corner. Since the legislation of the ‘Orphan Drug Act’ in 1983, there have been as many as 353 orphan drugs approved by the FDA. This has rendered at least 200 of the 7,000 known rare diseases treatable. Evidently, there is still a long way to go, but this brings to light an even greater tool, and one that is at each-and-everyone’s disposal.

80% of rare diseases are estimated to be of a ‘genetic origin’. This means that within our genome lies many of the answers as to why rare diseases occur. If scientists, clinicians and patients were able to understand the genetic basis of rare diseases, then the snow ball effect could be stopped, and rare diseases could be treated or even prevented in the future. However, in order to understand the human genome, it must be sequenced. This means taking genomes apart and citing every letter (A, T, C or G) it contains. Each person has a slightly different sequence of letters, which is what causes variation, as well as rare diseases. In the 1990s, sequencing the human genome would have taken you 15 years, intangible amounts of money and a global task force. Thanks to the age of technology we can now sequence a human genome, in months for less than $500.

Through the use of whole genome sequencing ending the rare disease odyssey could be brought forward. This would put a stop to the thousands of medical refugees, struggling to find where they belong in the medical world. This is because genome sequencing makes the genome and its secrets accessible to both the patient and their physician, accurately determining whether the patient has a rare disease based on their sequence of letters. Using this knowledge both patient and physician have the power to treat the diagnosed condition, prevent the onset of rare disease and find specialists who can make a real difference. Furthermore, once diagnosed, rare disease patients are able to connect with patients just like them. Diagnosis has the power to bring people together, allowing experiences of rare diseases to be shared. But this list of the benefits for genome sequencing does not stop at the patient and the physician.

The more genomes scientists’ sequence, the more variations of sequences can be observed and tested. This allows scientists to find new variations of sequences that cause rare disease. Once these variations are found and established, scientists will be able to research how these variations directly affect us. This will accelerate the development of treatments to stop the effects of rare diseases in their tracks.

Genome sequencing has the potential to empower the patient, the physician and the scientist. Therefore, if this opportunity comes you up, maybe you could consider it as you would be helping to change your life and the lives of others.

 

Dante Labs Launches Rare Disease Month February 2019

LONDON, January 31, 2019 /PRNewswire/ --

Rare Disease patients will receive whole genome sequencing and customized reports for $299 (€259). The revenues will fund free genetic tests for people in need. 

Global genomic company Dante Labs announced today the launch of an exclusive Whole Genome Sequencing Service for the month of February 2019 - Rare Disease Month 2019. This service, which includes whole genome sequencing 30X, data interpretation and additional mitochondrial DNA sequencing, is set to be reduced to $299 (€295) for Rare Disease patients.  

To qualify, patients simply need to upload their diagnosis after their order is placed. The promotion will run from February 1st -28th (Rare Disease Day) and is reserved to rare disease patients. Standard users will still benefit from a special discounted price ($399/€349).

Rare Disease patients will receive a customized report central to their diagnosis/disease of interest, with the most current research incorporated into their report. Along with the careful interpretation of their genetic data,  patients will also receive a general health and wellness report and a report on reaction to medications.

'Advocating for and supporting Rare Disease patients has always been part of our core mission' stated Dante Lab's CEO Andrea Riposati. "In 2018, we invested about $300K to subsidize genetic tests for rare disease communities, such as the Periodic Paralysis community."

With Rare Disease Month 2019, Dante Labs is building on this initiative, by extending support to the Rare Disease community further. Therefore, all sales during this promotion period will fund free genetic tests for rare disease patients in need during 2019.

"Whole genome sequencing is key for rare disease patients, as non-actionable variants can be aligned to symptoms and lead to better medicine management, empowering patients with a deeper understanding of their Rare Disease. With this exciting and rewarding promotion we feel proud to stand alongside patients to make genetic testing more accessible for everyone."

Contact: Francesco Pennelli
Phone: +39-3206030072

FEATURED IN

press
cnbc
press
press
certification